ATE264389T1 - Interleukin-5-spezifische rekombinante antikörper - Google Patents

Interleukin-5-spezifische rekombinante antikörper

Info

Publication number
ATE264389T1
ATE264389T1 AT95921931T AT95921931T ATE264389T1 AT E264389 T1 ATE264389 T1 AT E264389T1 AT 95921931 T AT95921931 T AT 95921931T AT 95921931 T AT95921931 T AT 95921931T AT E264389 T1 ATE264389 T1 AT E264389T1
Authority
AT
Austria
Prior art keywords
interleukin
recombinant antibodies
specific recombinant
specific
heavy
Prior art date
Application number
AT95921931T
Other languages
English (en)
Inventor
John Spencer Emtage
Mark William Bodmer
Diljeet Singh Athwal
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of ATE264389T1 publication Critical patent/ATE264389T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95921931T 1994-06-17 1995-06-16 Interleukin-5-spezifische rekombinante antikörper ATE264389T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412230A GB9412230D0 (en) 1994-06-17 1994-06-17 Interleukin-5 specific recombiant antibodies
PCT/GB1995/001411 WO1995035375A1 (en) 1994-06-17 1995-06-16 Interleukin-5 specific recombinant antibodies

Publications (1)

Publication Number Publication Date
ATE264389T1 true ATE264389T1 (de) 2004-04-15

Family

ID=10756925

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95921931T ATE264389T1 (de) 1994-06-17 1995-06-16 Interleukin-5-spezifische rekombinante antikörper

Country Status (18)

Country Link
US (3) US5998586A (de)
EP (1) EP0765392B1 (de)
JP (1) JP3973682B2 (de)
AT (1) ATE264389T1 (de)
AU (1) AU694783B2 (de)
CA (1) CA2192543C (de)
CZ (1) CZ292295B6 (de)
DE (1) DE69532889T2 (de)
ES (1) ES2218546T3 (de)
FI (1) FI965032L (de)
GB (1) GB9412230D0 (de)
HU (1) HU221641B1 (de)
IL (1) IL114179A (de)
NO (1) NO964808L (de)
NZ (1) NZ287927A (de)
SK (1) SK282625B6 (de)
WO (1) WO1995035375A1 (de)
ZA (1) ZA954990B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39548E1 (en) 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO1996021000A2 (en) * 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
TR200103046T2 (tr) 1999-04-23 2002-06-21 Pharmexa A/S IL5 aktivitesini düşürmek için yöntem.
CA2652733C (en) 2006-05-25 2016-06-21 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
WO2009120927A2 (en) 2008-03-28 2009-10-01 Smithkline Beecham Corporation Methods of treatment
US20170204191A1 (en) * 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
WO2012083370A1 (en) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
EP2691101A2 (de) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
MX2015008534A (es) 2012-12-26 2017-07-04 Oncosynergy Inc COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
TW201613615A (en) 2014-06-30 2016-04-16 Academia Sinica Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CA3064859A1 (en) 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
CN111065651B (zh) 2017-09-29 2023-07-14 江苏恒瑞医药股份有限公司 Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
EP3896085A4 (de) * 2018-12-12 2022-11-30 Shanghai Pharmaexplorer Co., Ltd. Monoklonaler antikörper gegen menschliches interleukin 5 (il-5) und dessen verwendung
KR20210145187A (ko) 2019-03-29 2021-12-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ZA898322B (en) * 1988-11-03 1990-11-28 Schering Corp Method of preventing or reducing eosinophilia
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
ATE171472T1 (de) * 1992-02-19 1998-10-15 Schering Corp Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies

Also Published As

Publication number Publication date
US6316227B1 (en) 2001-11-13
CZ371296A3 (cs) 1998-05-13
HU9603183D0 (en) 1997-01-28
NO964808L (no) 1997-02-17
NZ287927A (en) 1998-07-28
ES2218546T3 (es) 2004-11-16
CA2192543A1 (en) 1995-12-28
IL114179A (en) 2001-08-26
IL114179A0 (en) 1995-10-31
NO964808D0 (no) 1996-11-13
DE69532889D1 (de) 2004-05-19
FI965032A0 (fi) 1996-12-16
WO1995035375A1 (en) 1995-12-28
ZA954990B (en) 1996-12-17
CZ292295B6 (cs) 2003-08-13
US6734286B2 (en) 2004-05-11
JP3973682B2 (ja) 2007-09-12
EP0765392B1 (de) 2004-04-14
SK282625B6 (sk) 2002-10-08
JPH10501697A (ja) 1998-02-17
AU2680395A (en) 1996-01-15
GB9412230D0 (en) 1994-08-10
HU221641B1 (hu) 2002-12-28
HUT76672A (en) 1997-10-28
US5998586A (en) 1999-12-07
CA2192543C (en) 2008-07-29
EP0765392A1 (de) 1997-04-02
DE69532889T2 (de) 2005-03-10
AU694783B2 (en) 1998-07-30
SK160096A3 (en) 1997-06-04
FI965032A7 (fi) 1996-12-16
FI965032L (fi) 1996-12-16
US20020042089A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
ATE264389T1 (de) Interleukin-5-spezifische rekombinante antikörper
NO955167L (no) Monoklonalt anti-V-integrin-antistoff
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
DE68914244D1 (de) Monoklonaler Antikörper.
FI964845A7 (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
FI960567A7 (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
FI945865L (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69738312D1 (de) Hepatitis b monoklonale antikörper
TR199800517A3 (tr) Hümanize anti-hümen fas antikor.
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
NO890116L (no) Monoklonale antistoffer.
DE69023717D1 (de) Monoklonaler Antikörper.
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.
ITRM920223A0 (it) Anticorpi monoclonali anti-idiopici diretti contro anticorpi anti-tnf.
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
NO960683L (no) Monoklonalt antistoff som gjenkjenner interstitialcelle-overflateantigen
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
FI925638A7 (fi) Kasvainten yhteydessä esiintyvää antigeenia vastaan suunnattu monoklonaalinen vasta-aine 88BV59
DE69324928D1 (de) Monoklonaler antikörper
DE68916088D1 (de) Anti-CPBII-monoklonaler Antikörper.
FI935038A7 (fi) Kasvaimiin liittyvä monoklonaalinen vasta-aine 81AV78

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties